ERX 208
Alternative Names: ERX-208Latest Information Update: 06 Aug 2026
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer EtiraRx
- Class Antineoplastics; Benzamides; Small molecules
- Mechanism of Action Apoptosis stimulants; LIPA protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Ovarian cancer
Most Recent Events
- 06 Aug 2026 ERX 208 is still in preclinical development in Ovarian-cancer in USA (EtiraRx pipeline, August 2026)
- 28 Jul 2026 No recent reports of development identified for preclinical development in Ovarian-cancer in USA
- 22 Apr 2026 Pharmacodynamics data from a preclinical trial in Ovarian cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)